GLP-1s Tied to Weight Loss in Real-World Rheumatologic Care
The study examined the use of semaglutide and tirzepatide among patients with rheumatic and musculoskeletal diseases, finding that both treatments led to significant weight loss over one year. Tirzepatide users experienced greater weight loss compared to those using semaglutide, particularly among individuals without diabetes. The research highlights the varying efficacy of GLP-1 receptor agonists in real-world settings.
- ▪The use of semaglutide and tirzepatide among patients with RMDs increased from 0.1% in 2018 to 6.8% in 2024.
- ▪Tirzepatide users lost an average of 8.2% of body weight at 12 months, compared to 5.8% for semaglutide users.
- ▪Patients without diabetes lost 1.8% more weight than those with diabetes.
- ▪Tirzepatide users were nearly 50% more likely to lose at least 5% of body weight than semaglutide users.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/glp-1s-tied-weight-loss-real-world-rheumatologic-care-2026a1000gmt?src=rss |
| Publication time | Fri, 22 May 2026 04:12:50 EDT |
| Retrieval time | 2026-05-22T08:32:01.187Z |
| Last seen | 2026-05-22T08:32:01.187Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | FNIK0-aQK2uf |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:The use of semaglutide and tirzepatide increased over time among patients with rheumatic and musculoskeletal diseases (RMDs). Both treatments were associated with meaningful weight loss at 1 year, with greater reductions seen in tirzepatide users and in people without diabetes.METHODOLOGY:Researchers analyzed data from a rheumatology registry to describe initiation patterns of semaglutide and tirzepatide in patients with RMDs and to identify factors linked to weight loss.They included 60,198 adults with RMDs treated in US rheumatology practices between 2018 and 2024 (mean age, 57.0 years; 80.5% women).
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
